The measure is designed to end surprise medical billing and balance billing, taking the first step to implement the so-called No Surprises Act that passed Congress at the end of last year.
The Biden administration announced an interim final rule Thursday designed to end surprise medical billing and balance billing, taking the first step to implement the so-called No Surprises Act that passed Congress at the end of last year.
“No patient should forgo care for fear of surprise billing,” said HHS Secretary Xavier Becerra in a statement. “Health insurance should offer patients peace of mind that they won’t be saddled with unexpected costs.”
These out-of-pocket costs stem from health care provided in emergency and nonemergency situations from clinicians who are out of the consumer’s network in employer-sponsored and commercial health plans.
Balance billing, which is already prohibited in both Medicare and Medicaid, is when a provider charges the remainder of what an insurance plan did not pay.
As noted in a recent article in The American Journal of Managed Care®, the issue has broad bipartisan appeal, as two-thirds of commercially insured adults worry about unexpected medical bills, the COVID-19 pandemic has created new medical needs, and narrow networks are becoming more common.
The interim final rule bans:
Other rulemaking will address the arbitration process, which will use an independent dispute resolution process. Arbitrators will be able to consider in-network benchmarks, and prohibits them from considering either billed charges or public payer rates. They can also take into account a physician’s training and experience, as well as the acuity of their patients and complexity of their case mix.
The 411-page interim final rule will be open for 60 days for public comment following its publication in the Federal Register and will take effect for group health plans and health insurance issuers on or after January 1, 2022.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More